Background Despite optimum medical management, many patients with Parkinson's disease
are incapacitated by gait disorders including freezing of gait. We aimed to assess whether …

The “orbitofrontal” and “cingulate” frontostriatal loops and the mesolimbic dopaminergic
system that modulates their function have been implicated in theory of mind (ToM). Parkinson's …

Background Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment
of diabetes, has shown neuroprotective properties in a mouse model of Parkinson’s disease. …

Extensive published evidence supports the use of subcutaneously-administered
apomorphine as an effective therapy for Parkinson's disease (PD) but to date no consensus …

Objective: We sought to identify apathy metabolic bases in Parkinson disease (PD). Methods:
A total of 45 patients with PD who were not clinically depressed (Montgomery-Åsberg …

To report on OPTIPUMP, a cohort study, investigating the impact in real-life clinical settings
of continuous subcutaneous apomorphine infusion (CSAI) on the quality of life (HRQoL) of …

Background Insomnia is a frequent complaint of patients with Parkinson's disease, and it
negatively affects quality of life. Drugs that improve both sleep and parkinsonism would be of …

Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disease with limited
symptomatic treatment options. Aggregation of α‐synuclein in oligodendrocytes is believed to …

Behavioural disturbances such as disorders of mood, apathy or indifference are often observed
in Parkinson's disease (PD) patients with chronic high frequency deep brain stimulation …

The recognition of facial emotions is impaired following subthalamic nucleus (STN) deep
brain stimulation (DBS) in Parkinson's disease (PD). These changes have been linked to a …